---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017298"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T04:13:21.144098+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Windtree Q1 operating loss $4.1M, cash through May 2025; pivots to revenue via real estate

## Summary
- Operating loss $4.1M vs $4.4M prior year; net loss $5.0M ($4.63/share) vs net income $10.2M in Q1 2024.
- Cash and equivalents $1.2M at March 31, 2025; company believes funds operations only through May 2025.
- Closed private placement of Series D convertible preferred for $2.6M gross proceeds in April/May 2025.
- New strategy: secured right to buy a 436-unit multifamily property in Houston; signed supply agreement with Evofem for PHEXXI contraceptive gel.
- Istaroxime cardiogenic shock study enrolled; interim analysis of first 20 subjects expected in Q3 2025.

## SEC filing metadata
- accession: 0001437749-25-017298
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925017298/0001437749-25-017298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925017298/wint20250206_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017298
- JSON: https://secwatch.observer/filing/0001437749-25-017298.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.